A retrospective analysis of twice-daily cefotaxime compared to conventional therapy for the treatment of infections in a USA hospital

Diagn Microbiol Infect Dis. 1995 May-Jun;22(1-2):167-9. doi: 10.1016/0732-8893(95)00102-g.

Abstract

A retrospective, matched cohort study was performed to determine the cost outcomes among 495 hospitalized patients who received twice-daily dosing of cefotaxime and 3949 matched cohorts who received other antibiotics. By an attribution model, twice-daily use was associated with shorter mean lengths of stay (-0.498 day, P < .7) and lower mean total costs of hospitalization (-$623, P < .8). Twice-daily dosing of cefotaxime is commonly employed for the treatment of a variety of serious infections, and appears to be cost effective.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / economics
  • Anti-Bacterial Agents / therapeutic use
  • Bacterial Infections / drug therapy*
  • Bacterial Infections / economics*
  • Bacterial Infections / microbiology
  • Cefotaxime / administration & dosage
  • Cefotaxime / economics
  • Cefotaxime / therapeutic use*
  • Cephalosporins / administration & dosage
  • Cephalosporins / economics
  • Cephalosporins / therapeutic use*
  • Child
  • Cohort Studies
  • Cost-Benefit Analysis
  • Drug Administration Schedule
  • Female
  • Health Care Costs
  • Humans
  • Length of Stay
  • Male
  • Middle Aged
  • Retrospective Studies
  • Treatment Outcome
  • United States

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • Cefotaxime